Will the humanized monoclonal antibody CM310 transform treatment outcomes for patients with atopic dermatitis?

In this episode, we speak with Dr. Jianzhong Zhang, Professor at Peking University People’s Hospital, who introduces a breakthrough drug for atopic dermatitis called CM310 and discusses its potential to improve the quality of life for patients living with this chronic skin condition.

In 2024, Dr. Zhang and his collaborators published the results of a pivotal clinical trial evaluating the efficacy and safety of CM310. The article is titled, “Efficacy and safety of CM310 in moderate-to-severe atopic dermatitis: A multicenter, randomized, double-blind, placebo-controlled phase 2b trial.”

Guest: Dr. Jianzhong Zhang
Host: John L

Summary:

We explore the potential of a monoclonal antibody drug—named CM310—for treating atopic dermatitis, focusing on the results of a clinical trial conducted in China and published in the Chinese Medical Journal.

Can cardiovascular health (CVH) assessment based on Life’s Essential 8 framework help prevent non-communicable diseases?

In this episode, we speak with Dr. Ningjian Wang, Professor at the School of Medicine, Shanghai Jiao Tong University, who explains the American Heart Association’s cardiovascular health framework called ‘Life’s Essential 8’ and its association with the risk of non-communicable chronic diseases (NCDs).

The potential role of Life’s Essential 8 in preventing NCDs and promoting cardiovascular health is the focus of an article by Dr. Wang and collaborators published in Chinese Medical Journal. The article is titled, “Life's Essential 8 and risk of non-communicable chronic diseases: Outcome-wide analyses.”

Guest: Dr. Ningjian Wang
Host: John L

Summary:

We explore the link between cardiovascular health assessed using the Life’s Essential 8 framework and the risk of non-communicable diseases, based on evidence from a study published in Chinese Medical Journal

Is mass drug administration effective against trachoma—a devastating infectious disease that causes blindness—in endemic countries?
 
 We speak with Dr. Tao Xiong, Professor in the Department of Pediatrics from West China Second University Hospital at Sichuan University, who attempts to address this question in a recent systematic review of the current evidence, and discusses how mass drug administration may need to be modified according to the endemicity of trachoma in a particular region. 

In this second episode, we discuss this review article by Dr. Xiong and collaborators published recently in the Chinese Medical Journal. The article is titled, “Effectiveness of azithromycin mass drug administration on trachoma: a systematic review”.

Guest: Prof. Tao Xiong
Host: Dr. Laura Moro